214 related articles for article (PubMed ID: 20884255)
1. The impact of sunitinib-induced hypothyroidism on progression-free survival of metastatic renal cancer patients: a prospective single-center study.
Baldazzi V; Tassi R; Lapini A; Santomaggio C; Carini M; Mazzanti R
Urol Oncol; 2012 Sep; 30(5):704-10. PubMed ID: 20884255
[TBL] [Abstract][Full Text] [Related]
2. Does sunitinib-induced hypothyroidism play a role in the activity of sunitinib in metastatic renal cell carcinoma?
Sella A; Hercbergs AH; Hanovich E; Kovel S
Chemotherapy; 2012; 58(3):200-5. PubMed ID: 22759787
[TBL] [Abstract][Full Text] [Related]
3. Hypothyroidism in patients with renal cell carcinoma: blessing or curse?
Schmidinger M; Vogl UM; Bojic M; Lamm W; Heinzl H; Haitel A; Clodi M; Kramer G; Zielinski CC
Cancer; 2011 Feb; 117(3):534-44. PubMed ID: 20845482
[TBL] [Abstract][Full Text] [Related]
4. Sunitinib-induced hypothyroidism predicts progression-free survival in metastatic renal cell carcinoma patients.
Buda-Nowak A; Kucharz J; Dumnicka P; Kuzniewski M; Herman RM; Zygulska AL; Kusnierz-Cabala B
Med Oncol; 2017 Apr; 34(4):68. PubMed ID: 28343336
[TBL] [Abstract][Full Text] [Related]
5. Hyperlipidemia and hypothyroidism among metastatic renal cell carcinoma patients taking sunitinib malate. Related or unrelated adverse events?
Tassi R; Baldazzi V; Lapini A; Carini M; Mazzanti R
Clin Genitourin Cancer; 2015 Apr; 13(2):e101-5. PubMed ID: 25450040
[TBL] [Abstract][Full Text] [Related]
6. [Thyroid dysfunction in patients with advanced renal cell carcinoma treated with sunitinib: a multifactorial issue].
Fuertes Zamorano N; De Miguel Novoa MP; Molino González A; Díaz Pérez JÁ; Rojas-Marcos PM; Montañez Zorrilla MC
Endocrinol Nutr; 2010 Dec; 57(10):486-91. PubMed ID: 20702151
[TBL] [Abstract][Full Text] [Related]
7. Is sunitinib-induced hypothyroidism a predictive clinical marker for better response in metastatic renal cell carcinoma patients?
Bozkurt O; Karaca H; Hacıbekiroglu I; Kaplan MA; Duzkopru Y; Uysal M; Berk V; Inanc M; Duran AO; Ozaslan E; Ucar M; Ozkan M
J Chemother; 2016 Jun; 28(3):230-4. PubMed ID: 25948423
[TBL] [Abstract][Full Text] [Related]
8. Thyroid Dysfunction in Patients with Metastatic Carcinoma Treated with Sunitinib: Is Thyroid Autoimmunity Involved?
Pani F; Atzori F; Baghino G; Boi F; Tanca L; Ionta MT; Mariotti S
Thyroid; 2015 Nov; 25(11):1255-61. PubMed ID: 26414109
[TBL] [Abstract][Full Text] [Related]
9. [Treatment with sunitinib and hypothyroidism--a case report and overview of literature].
Kreze A; Stáhalová V; Zadrazilová A; Koskuba J; Kosák M
Klin Onkol; 2009; 22(4):176-8. PubMed ID: 19731880
[TBL] [Abstract][Full Text] [Related]
10. Hypothyroidism correlates with a better prognosis in metastatic renal cancer patients treated with sorafenib or sunitinib.
Riesenbeck LM; Bierer S; Hoffmeister I; Köpke T; Papavassilis P; Hertle L; Thielen B; Herrmann E
World J Urol; 2011 Dec; 29(6):807-13. PubMed ID: 21153827
[TBL] [Abstract][Full Text] [Related]
11. Sunitinib-induced hypothyroidism is due to induction of type 3 deiodinase activity and thyroidal capillary regression.
Kappers MH; van Esch JH; Smedts FM; de Krijger RR; Eechoute K; Mathijssen RH; Sleijfer S; Leijten F; Danser AH; van den Meiracker AH; Visser TJ
J Clin Endocrinol Metab; 2011 Oct; 96(10):3087-94. PubMed ID: 21816788
[TBL] [Abstract][Full Text] [Related]
12. Clinical significance of sunitinib-associated macrocytosis in metastatic renal cell carcinoma.
Bourlon MT; Gao D; Trigero S; Clemons JE; Breaker K; Lam ET; Flaig TW
Cancer Med; 2016 Dec; 5(12):3386-3393. PubMed ID: 27758076
[TBL] [Abstract][Full Text] [Related]
13. Frequent dose interruptions are required for patients receiving oral kinase inhibitor therapy for advanced renal cell carcinoma.
La Vine DB; Coleman TA; Davis CH; Carbonell CE; Davis WB
Am J Clin Oncol; 2010 Jun; 33(3):217-20. PubMed ID: 19745694
[TBL] [Abstract][Full Text] [Related]
14. Hypothyroidism in patients with metastatic renal cell carcinoma treated with sunitinib.
Rini BI; Tamaskar I; Shaheen P; Salas R; Garcia J; Wood L; Reddy S; Dreicer R; Bukowski RM
J Natl Cancer Inst; 2007 Jan; 99(1):81-3. PubMed ID: 17202116
[TBL] [Abstract][Full Text] [Related]
15. The use of sunitinib in renal cell carcinoma: where are we now?
Czarnecka AM; Szczylik C; Rini B
Expert Rev Anticancer Ther; 2014 Sep; 14(9):983-99. PubMed ID: 25066545
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity and biomarker analysis of sunitinib in patients with bevacizumab-refractory metastatic renal cell carcinoma.
Rini BI; Michaelson MD; Rosenberg JE; Bukowski RM; Sosman JA; Stadler WM; Hutson TE; Margolin K; Harmon CS; DePrimo SE; Kim ST; Chen I; George DJ
J Clin Oncol; 2008 Aug; 26(22):3743-8. PubMed ID: 18669461
[TBL] [Abstract][Full Text] [Related]
17. First-line treatment with sunitinib for type 1 and type 2 locally advanced or metastatic papillary renal cell carcinoma: a phase II study (SUPAP) by the French Genitourinary Group (GETUG)†.
Ravaud A; Oudard S; De Fromont M; Chevreau C; Gravis G; Zanetta S; Theodore C; Jimenez M; Sevin E; Laguerre B; Rolland F; Ouali M; Culine S; Escudier B
Ann Oncol; 2015 Jun; 26(6):1123-1128. PubMed ID: 25802238
[TBL] [Abstract][Full Text] [Related]
18. Could thyroid dysfunction influence outcome in sunitinib-treated metastatic renal cell carcinoma?
Sabatier R; Eymard JC; Walz J; Deville JL; Narbonne H; Boher JM; Salem N; Marcy M; Brunelle S; Viens P; Bladou F; Gravis G
Ann Oncol; 2012 Mar; 23(3):714-721. PubMed ID: 21653681
[TBL] [Abstract][Full Text] [Related]
19. Sunitinib in advanced metastatic non-clear cell renal cell carcinoma: a single institution retrospective study.
Paglino C; Imarisio I; Ganini C; Morbini P; Vercelli A; Bregant C; Porta C
Future Oncol; 2012 Dec; 8(12):1605-12. PubMed ID: 23231522
[TBL] [Abstract][Full Text] [Related]
20. Sunitinib-induced thyrotoxicosis - a not so rare entity.
Jazvić M; Prpić M; Jukić T; Murgić J; Jakšić B; Kust D; Prgomet A; Bolanča A; Kusić Z
Anticancer Res; 2015 Jan; 35(1):481-5. PubMed ID: 25550591
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
